H.B. Fuller's Strategic Stand: Why It Rejected Ancora's $1.2B Bid

ST. PAUL, MN – August 24, 2026 – In a move that signals a firm defense of its long-term strategy, the Board of Directors at H.B. Fuller has unanimously rejected an unsolicited proposal from activist investor Ancora Holdings Group to acquire its Building Adhesives Solutions (BAS) business for up to $1.2 billion. The decision sets the stage for a potential showdown over the future of the world's largest pureplay adhesives company, pitting the board's vision of integrated growth against the activist's call for immediate deleveraging and asset sales.

The rejection, detailed in a public letter, was unequivocal. The board argued that Ancora's offer "materially undervalues" the BAS segment, ignores its growth potential, and fails to appreciate its strategic importance within the company's highly integrated global operations. This isn't just a negotiation over price; it's a fundamental clash of corporate philosophies.

A Question of Value and Vision

At the core of H.B. Fuller's rebuttal is the conviction that the BAS business is worth far more to the company than Ancora's $1.1 billion to $1.2 billion cash offer suggests. Based on the segment's 2025 adjusted EBITDA of $134 million, Ancora's bid implies a valuation multiple of roughly 8.2x to 8.9x. The board, supported by independent advisors, deemed this "substantially below precedent transactions."

Industry data lends credence to this position. While median M&A multiples in the broader chemicals sector hovered around 8.8x in 2024, private equity deals and transactions for specialty chemical assets have commanded higher premiums, often reaching 10x to 12.2x EBITDA or more. Given that the global construction adhesives market is projected to grow robustly, with some estimates predicting a market size near $20 billion by 2030, H.B. Fuller's leadership sees significant upside that Ancora's offer fails to capture.

The company pointed to recent performance as proof of the segment's momentum. "In the second quarter, BAS demonstrated its performance momentum by delivering organic growth of 6% year-over-year... and a 10% EBITDA improvement," stated Teresa J. Rasmussen, Chair of the Board, in the company's official response. Leadership expects this trajectory to continue as construction markets recover and new drivers, such as the massive buildout of data centers, create sustained demand.

This defense is not just about the BAS unit in isolation. It’s about its role in a broader strategic transformation. The company is simultaneously executing on its recent £715 million acquisition of U.K.-based Advanced Medical Solutions (AMS) and its internal restructuring program, 'Project Quantum Leap.' The AMS deal is designed to pivot H.B. Fuller toward the higher-growth, higher-margin medical adhesives market. The board argues that the cash flow from a healthy BAS business is critical to supporting this transformation and its plan to rapidly deleverage within two years of the AMS deal closing.

The Activist's Playbook in Action

The challenge comes from a formidable and experienced activist. Cleveland-based Ancora Holdings has a well-documented history of successfully pressuring boards at companies like Norfolk Southern, C.H. Robinson, and Berry Global to enact changes. Their approach with H.B. Fuller follows a familiar pattern: identify a perceived undervaluation, criticize the current leadership's strategy, and propose a specific action—in this case, a divestiture—to unlock shareholder value.

Ancora publicly frames the BAS business as a "lower margins" segment in a "highly fragmented market." Their primary argument is that selling the unit is the most effective way for H.B. Fuller to address its debt load, which they claim is exacerbated by poor free cash flow conversion. In a sharp retort to the board's rejection, Ancora's leadership criticized the lack of direct engagement, labeling the decision "irrational" and a sign of "entrenchment." The activist firm insists it has the capacity to self-finance the deal and has hinted at other interested parties, all while raising the specter of a proxy contest to change the board's composition.

This public sparring highlights a classic tension in modern corporate governance. H.B. Fuller's board is championing a long-term, integrated strategy that it believes will create sustainable value, even if it requires patience. Ancora, representing a faction of shareholders, is demanding more immediate action to address the balance sheet and stock performance, arguing that the board's strategic path is too slow or misguided.

Beyond the Balance Sheet: The Tangled Web of a Carve-Out

A crucial, and perhaps decisive, element of H.B. Fuller's argument lies in the operational complexity of its business. The company is not a holding company of disparate assets but a "pureplay adhesives" manufacturer with a deeply integrated global footprint. The board's letter highlighted this by noting that a carve-out of BAS would create "material operating inefficiencies" because the unit "shares manufacturing with H.B. Fuller’s other businesses in over thirty plants around the world."

This claim goes to the heart of the column's focus—the 'why' behind the operations. Separating a business unit that is woven into a global supply chain is far from a simple transaction. It would likely require creating costly standalone IT, finance, and HR systems, negotiating complex Transitional Service Agreements (TSAs), and physically separating production lines. These dis-synergies, the board argues, would "materially offset" the financial benefits of debt reduction.

This operational entanglement is further complicated by H.B. Fuller's own massive restructuring effort, 'Project Quantum Leap.' This multi-year plan aims to consolidate its manufacturing footprint from 82 to 55 facilities by 2030, a move projected to generate $75 million in annual savings. Forcing an unplanned divestiture in the middle of this carefully orchestrated optimization could throw the entire strategy into disarray, creating stranded costs and disrupting efficiencies for both the parent company and the newly independent BAS. For the board, Ancora's proposal isn't just financially inadequate; it's operationally reckless.

The standoff leaves H.B. Fuller at a crossroads. The board has drawn a clear line, betting its credibility on a future built on strategic acquisitions and operational integration. Ancora has made it clear it does not intend to back down, setting the stage for a protracted battle over the company’s direction and who is best equipped to steer it forward.